血清内脏脂肪素、脂联素与非酒精性脂肪性肝病临床病理的关系

朱超慧; 陈东风; 艾正琳; 杨丽; 闵敏

血清内脏脂肪素、脂联素与非酒精性脂肪性肝病临床病理的关系

1. 解放军309医院消化科
2. 第三军医大学大坪医院消化科

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2755
- HTML全文浏览量: 13
- PDF下载量: 984
- 被引次数: 0
出版历程
- 出版日期: 2011-07-20

Relationship between serum visfatin and serum adiponectin level and the pathology of nonalcoholic fatty liver disease

摘要

摘要: 目的探讨NAFLD临床病理改变与血清内脏脂肪素(visfatin)、脂联素(adiponectin)水平的相关性。方法取54例患者肝组织标本,根据其病理改变分为正常对照组(Control组)、单纯性脂肪肝组(SS组)、非酒精性脂肪性肝炎(NASH组)。酶联免疫法测定所有患者的血清visfatin、adiponectin水平,并比较各组之间visfatin、adiponectin的差异。结果 54例标本中:Control组23例,SS组11例,NASH组20例。NASH组血清visfatin低于Control组(P=0.012)和SS组(P=0.021);SS组血清visfatin较Control组有降低的趋势;Control组血清adiponectin高于NASH组(P=0.024)和SS组(P=0.039);NASH组较SS组有降低的趋势。结论在NAFLD患者中,随着肝组织脂肪变及炎症的加重,其血清visfatin、adiponectin水平逐渐降低。
- 脂肪肝 /
- 内脏脂肪素,脂联素
Abstract: Objective To explore the relationship between serum visfatin and adiponectin levels and the pathology of NAFLD.Methods 54 patients were divided into 3 groups according to the pathology, including control group, simple steatosis group, and nonalcoholic steatohepatitis group.Serum visfatin and adiponectin levels were measured by enzymelinked immunosorbent assay.Results Among the 54 patients, control group includes 23 cases;simple steatosis group comprises of 11 cases;while nonalcoholic steatohepatitis group contains 20 cases.The level of serum visfatin of NASH group is lower than that of control group and simple steatosis group.Moreover, the change of serum adiponectin of NASH is as same as serum visfatin.Conclusion In NAFLD patients, the more severe the changes of steatosis and inflammation of the histopathology in liver, the lower levels of visfatin and adiponectin in plasma concentrations were showed.
- fatty liver /
- visfatin

HTML全文

参考文献(11)

[1]Musso G, Gambino R, Cassader M.Non-alcoholic fatty liverdisease from pathogenesis to management:an update[J].Obes Rev, 2010, 11 (6) :430-445.

[2]Kamada Y, Takehara T, Hayashi N.Adipocytokines and liverdisease[J].J Gastroenterol, 2008, 43 (11) :811-822.

[3]Low S, Chin MC, Ma S, et al.Rationale for redefining obesityin Asians[J].Ann Acad Med Singapore, 2009, 38 (1) :66-69.

[4]中华医学会.非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志, 2006, 14 (3) :161-163.

[5]沙卫红, 李瑜元.2009年美国消化疾病会议周概况[J].中华消化杂志, 2009, 29 (8) :547-549.

[6]Fierbinteanu-Braticevici C, Dina I, Petrisor A, et al.Noninvasiveinvestigations for non alcoholic fatty liver disease and liverfibrosis[J].World J Gastroenterol, 2010, 16 (38) :4784-4791.

[7]Lewis JR, Mohanty SR.Nonalcoholic fatty liver disease:areview and update[J].Dig Dis Sci, 2010, 55 (3) :560-578.

[8]Balsano C, Alisi A, Nobili V.Liver fibrosis and therapeuticstrategies:the goal for improving metabolism[J].Curr DrugTargets, 2009, 10 (6) :505-512.

[9]Lonardo A, Carani C, Carulli N, et al.'Endocrine NAFLD'ahormonocentric perspective of nonalcoholic fatty liver diseasepathogenesis[J].J Hepatol, 2006, 44 (6) :1196-1207.

[10]Fukuhara A, Matsuda M, Nishizawa M, et al.Visfatin:a proteinsecreted by visceral fat that mimics the effects of insulin[J].Science, 2005, 307 (5708) :426-430.

[11]Targher G, Bertolini L, Rodella S, et al.Associations betweenplasma adiponectin concentrations and liver histologyin patients with nonalcoholic fatty liver disease[J].ClinEndocrinol (Oxf) , 2006, 64 (6) :679-683.

施引文献

资源附件(0)

访问统计